NCT01111214

Child Pneumococcal Serotype Epidemiology In Greece

Incidence And Serotypes Of Invasive Pneumococcal Disease, After The Introduction Of The Heptavalent Conjugated Vaccine In Greece

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 457 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 14 Years
• Healthy volunteers: Not accepted

Summary

Streptococcus pneumoniae is a major cause of pneumonia, sepsis, bacteremia, and pneumococcal meningitis among infants and children worldwide. The 7-valent conjugate pneumococcal vaccine (Prevenar) has been introduced in the Greek Market in 2004. Additionally, as of 2006 Prevenar has been included in the Greek National Immunization Program. The effect of the mass vaccination on the incidence of pneumococcal serotypes involved in the occurring invasive pneumococcal disease, is an important factor to consider for the introduction of the 13-valent pneumococcal conjugate vaccine.

Detailed description

open label, one group Purposive sampling of hospitalized children ≤14 years of age with confirmed IPD

Conditions

• Pneumococcal Disease

Interventions

Type	Name	Description
OTHER	no intervention	There is no intervention. This is a non interventional study.

Timeline

• Start date: 2011-11-01
• Primary completion: 2012-11-01
• Completion: 2012-11-01
• First posted: 2010-04-27
• Last updated: 2013-01-10

Locations

9 sites across 1 country: Greece